

Lyon (France), Philadelphia (USA), April 15, 2009,

**ERYtech Pharma** will present very encouraging results of its R&D platform at the annual meeting of the American Association of Cancer Research at the Colorado Convention Center in Denver (CO) between 18th to 21th April.

Three subjects will be exposed on posters:

- ***In situ* dendritic cells-based cancer immunotherapy: antigen carried by erythrocytes targets Dendritic Cells**
- **Allosteric hemoglobin effector loaded erythrocytes improve the efficacy of radiotherapy**
- **Efficacy of L-asparaginase loaded red blood cells in combination with gemcitabine in mice bearing PANC-1 ( pancreatic carcinoma)**

These different applications show the innovative capacities of the ERYtech Pharma technology.

Sunday, April 19, 2009

*In situ* dendritic cells-based cancer immunotherapy: antigen carried by erythrocytes targets DC

8:00 am - 12:00 pm - Poster Session Cancer Vaccines: Preclinical and Animal Models

Immunology 1 Hall B-F, Poster Section 16, Poster Board Number 6, #351

Monday, April 20, 2009

Allosteric hemoglobin effector loaded erythrocytes improve the efficacy of radiotherapy

1:00 pm - 5:00 pm - Poster Session Radiosensitizers and Radioprotectors

Tumor Biology 24 Hall B-F, Poster Section 9, Poster Board Number 10, #2299

Tuesday, April 21, 2009

Efficacy of L-asparaginase loaded red blood cells in combination with gemcitabine in mice bearing PANC-1

1:00 pm - 5:00 pm - Poster Session Combination Chemotherapy 2

Experimental and Molecular Therapeutics 31 Hall B-F, Poster Section 33 Poster Board Number 27, #4594

**About ERYtech Pharma** <http://www.erytech.com>

ERYtech Pharma is a specialty pharma company developing a new generation of drugs. GRASPA®, its most advanced product, has achieved its Phase II clinical trial in Acute Lymphoblastic Leukemia.

A pioneer in the encapsulation of therapeutic molecules into red blood cells, ERYtech Pharma is developing a pipeline of innovative therapeutic solutions based on its proprietary technology and expertise in the physiological properties of erythrocytes. The company addresses serious pathologies, orphan indications or sub-populations of patients, particularly in the fields of haematology, cancer and metabolic diseases.

**Contact Presse : Cathy CLEMENT – GAIA Communication**

Tel : (0)1 30 82 66 65 – [cathy.clement@gaiacommunication.fr](mailto:cathy.clement@gaiacommunication.fr)

**Autres contacts :**

**ERYtech Pharma- 60, Avenue Rockefeller – Bâtiment Adénine – 69008 - LYON - France**

Tel : +33 (0) 4 78 74 44 38 - Fax : +33 (0) 4 78 75 56 29

[contact@erytech.com](mailto:contact@erytech.com)

**ERYtech Pharma - US Office - 3711 Market Street, 4<sup>th</sup> Floor - 19104 Philadelphia PA  
- USA**

Phone: 1 (267) 499 2031- Fax: 1 (215) 966 6101

[\*\*www.erytech.com\*\*](http://www.erytech.com)